1. 224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). (24th November 2019) Authors: Friedlander, M L; Moore, K N; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E; Hettle, R; Flood, E; Disilvestro, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). (23rd October 2018) Authors: O'Cearbhaill, R E; Wolfer, A; Disilvestro, P; O'Malley, D M; Sabbatini, P; Shohara, L; Schwarzenberger, P O; Ricciardi, T; Macri, M; Ryan, A; Venhaus, R R; Bryan, J K; Wong, P; Homicsko, K; Kandalaft, L; Rusakiewicz, S; Harari, A; Monk, B J; Coukos, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA3Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. (25th November 2018) Authors: Friedlander, M; Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A M; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E S; Bloomfield, R; Disilvestro, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗